Nomura Q4 2026 slides: annual records set despite profit decline

Nomura reported record full-year net income of ¥362.1 billion, up 6%, with ROE of 10.1% meeting its 2030 Vision target three years early. However, fourth-quarter net income fell 19% sequentially to ¥73.9 billion and income before taxes dropped 20%, driving a 2.66% premarket decline in the stock to $8.05. The company also raised its annual dividend to ¥51 per share and maintained strong capital and liquidity, including a 12.9% CET1 ratio and 214% LCR.

Analysis

Nomura’s setup is less about the headline quarterly dip and more about the mix shift underneath: the firm is converting cyclical brokerage/banking revenue into a larger recurring-fee base, which should compress earnings volatility and justify a higher multiple over time. The key second-order winner is not the traded-name bank per se, but adjacent private markets and asset-gathering businesses in Japan, where rising household allocation and institutional demand can compound with very low incremental capital intensity.

The near-term issue is that the market is likely to punish any sign that revenue quality is improving faster than near-term P&L, because acquired assets, impairment noise, and international softness create a “show me” gap. That matters because this type of transition typically rerates only after two or three clean quarters of stable-margin delivery; until then, the stock can lag despite better strategic fundamentals. Also, the strong capital position gives management room to keep returning cash, but it can’t offset skepticism if global markets remain choppy and underwriting activity normalizes down.

Contrarian takeaway: the consensus is probably underestimating how fast the stable-fee engine can offset transaction cyclicality, while overestimating the durability of the current quarterly weakness. If Wealth Management inflows keep compounding and AUM remains elevated, Nomura’s earnings floor rises meaningfully, and the operating leverage in Japan’s capital markets franchise becomes more visible. The risk is that international wholesale softness persists longer than expected, keeping near-term EPS muted even as the strategic case improves.

Key Decisions for Investors

• Buy NMR on 1-3 month weakness; target a re-rating as the market prices in recurring-fee durability. Upside is strongest if the next two quarters confirm stable revenue growth; stop if Wealth Management inflows or recurring revenue decelerate materially.
• Pair trade: long NMR / short a more transaction-dependent Asian broker or Japanese financial intermediary over the next 3-6 months. The relative trade favors the name with improving fee mix and stronger capital return capacity.
• For event-driven accounts, sell cash-secured puts on NMR with 2-4 month tenor around the current premarket-implied downside. You’re being paid to own a capitalized balance sheet while waiting for sentiment to reset.
• Watch for a catalyst in the next earnings cycle: if investment banking and wholesale stabilize, add to NMR on confirmation rather than anticipation. The market will likely re-rate only after one clean quarter, not on strategy alone.